1. Home
  2. RVLV vs BRVE Comparison

RVLV vs BRVE Comparison

Compare RVLV & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolve Group Inc.

RVLV

Revolve Group Inc.

BUY

Current Price

$21.63

Market Cap

1.5B

ML Signal

BUY

Logo Braveheart Bio Inc. Common Stock

BRVE

Braveheart Bio Inc. Common Stock

N/A

Current Price

$19.09

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RVLV
BRVE
Founded
2003
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2018
2026

Fundamental Metrics

Financial Performance
Metric
RVLV
BRVE
Price
$21.63
$19.09
Analyst Decision
Buy
Strong Buy
Analyst Count
15
5
Target Price
$30.85
★ $45.25
AVG Volume (30 Days)
★ 675.4K
502.7K
Earning Date
11-03-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.64
N/A
EPS
★ 0.46
N/A
Revenue
★ $1,225,682,000.00
N/A
Revenue This Year
$13.31
N/A
Revenue Next Year
$9.03
N/A
P/E Ratio
$46.07
★ N/A
Revenue Growth
★ 8.48
N/A
52 Week Low
$17.35
$18.56
52 Week High
$31.68
$32.00

Technical Indicators

Market Signals
Indicator
RVLV
BRVE
Relative Strength Index (RSI) 49.64 33.35
Support Level $21.36 N/A
Resistance Level $22.11 $29.71
Average True Range (ATR) 0.68 2.33
MACD 0.15 -0.40
Stochastic Oscillator 62.99 6.62

Price Performance

Historical Comparison
RVLV
BRVE

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

About BRVE Braveheart Bio Inc. Common Stock

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

Share on Social Networks: